Next-Generation Hydrocortisone Delivery Systems

This inventive concept envisions a new generation of hydrocortisone delivery systems that leverage cutting-edge technologies to provide precision-controlled, personalized, and adaptive dosing regimens for various therapeutic applications.

The original patent disclosed an aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol. However, this formulation has limitations in terms of dosing flexibility, patient-specific needs, and real-time monitoring. The new inventive concept addresses these limitations by introducing innovative delivery systems that integrate advanced materials, wearable technologies, machine learning algorithms, and bioresponsive polymers.

The new claims describe a range of next-generation hydrocortisone delivery systems. These include a wearable, transdermal patch with individually addressable micro-reservoirs for customizable dosing profiles; a machine learning-based method for personalized immunosuppression therapy; a pharmaceutical formulation featuring a novel, bioresponsive polymer that selectively releases hydrocortisone sodium phosphate in response to changes in skin pH or temperature; a hydrocortisone-based treatment for rare genetic disorders characterized by cortisol deficiency, administered via a nasal spray device with an integrated, AI-powered dosing controller; and a modular, implantable device for sustained-release hydrocortisone delivery, comprising biodegradable capsules that can be programmed to release the active ingredient at specific times and rates.

The new claims introduce significant innovations in hydrocortisone delivery, including the use of wearable technologies, machine learning algorithms, bioresponsive polymers, and implantable devices. These advancements provide unprecedented levels of precision, personalization, and adaptability in hydrocortisone dosing, making the original patent's formulation obsolete.

Other possible embodiments of the inventive concept could include oral formulations with integrated sensors, injectable systems with real-time monitoring, or topical creams with adaptive release profiles. These variations could be achieved through the use of different materials, device architectures, or software algorithms.

The next-generation hydrocortisone delivery systems have significant commercial potential in various therapeutic areas, including immunosuppression, dermatology, and rare genetic disorders. The target markets include pharmaceutical companies, medical device manufacturers, and healthcare providers seeking to improve patient outcomes and reduce treatment costs.